Insider Selling: Bicycle Therapeutics (NASDAQ:BCYC) CEO Sells 5,905 Shares of Stock

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) CEO Kevin Lee sold 5,905 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $4.27, for a total value of $25,214.35. Following the completion of the sale, the chief executive officer owned 605,408 shares of the company’s stock, valued at $2,585,092.16. The trade was a 0.97% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kevin Lee also recently made the following trade(s):

• On Monday, July 6th, Kevin Lee sold 1,737 shares of Bicycle Therapeutics stock. The stock was sold at an average price of $4.31, for a total value of $7,486.47.

Bicycle Therapeutics Stock Performance

BCYC traded up $0.03 during trading on Tuesday, hitting $4.38. 506,264 shares of the stock were exchanged, compared to its average volume of 439,849. The firm has a 50 day simple moving average of $4.40 and a 200 day simple moving average of $5.27. The firm has a market cap of $305.77 million, a price-to-earnings ratio of -1.39 and a beta of 1.55. Bicycle Therapeutics PLC Sponsored ADR has a 1 year low of $3.92 and a 1 year high of $9.18.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its earnings results on Thursday, April 30th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.25). The firm had revenue of $0.89 million during the quarter, compared to analysts’ expectations of $7.50 million. Bicycle Therapeutics had a negative return on equity of 35.74% and a negative net margin of 344.95%. As a group, equities analysts anticipate that Bicycle Therapeutics PLC Sponsored ADR will post -1.97 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently commented on BCYC. Morgan Stanley reduced their price target on shares of Bicycle Therapeutics from $13.00 to $12.00 and set an “equal weight” rating for the company in a report on Wednesday, April 8th. Royal Bank Of Canada dropped their price objective on shares of Bicycle Therapeutics from $11.00 to $7.00 and set a “sector perform” rating on the stock in a research note on Wednesday, March 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Bicycle Therapeutics in a report on Friday, April 10th. Wall Street Zen raised shares of Bicycle Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 27th. Finally, Citizens Jmp lowered their target price on Bicycle Therapeutics from $12.00 to $8.00 and set a “market outperform” rating for the company in a report on Wednesday, March 18th. Five research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $14.00.

Institutional Trading of Bicycle Therapeutics

Institutional investors have recently modified their holdings of the company. Armistice Capital LLC boosted its stake in Bicycle Therapeutics by 8.7% in the fourth quarter. Armistice Capital LLC now owns 3,236,000 shares of the company’s stock valued at $22,911,000 after acquiring an additional 258,000 shares in the last quarter. Long Focus Capital Management LLC grew its holdings in Bicycle Therapeutics by 7.7% in the third quarter. Long Focus Capital Management LLC now owns 1,418,695 shares of the company’s stock worth $10,981,000 after purchasing an additional 101,402 shares during the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new position in shares of Bicycle Therapeutics during the fourth quarter worth $954,000. Flax Pond Capital LLC purchased a new stake in shares of Bicycle Therapeutics during the 4th quarter valued at $1,229,000. Finally, Ausdal Financial Partners Inc. purchased a new stake in shares of Bicycle Therapeutics during the 2nd quarter valued at $70,000. 86.15% of the stock is currently owned by institutional investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.